Background {#Sec1}
==========

Lymphangioleiomyomatosis (LAM) is a rare multisystem neoplastic disease that is characterized by cystic lung destruction, angiomyolipoma and lymphangioleiomyomas \[[@CR1], [@CR2]\]. LAM may occur sporadically, or in adults with tuberous sclerosis complex \[[@CR1]\]. Cystic remodeling in the lungs compromises lung function, resulting in progressive dyspnea, and finally respiratory failure \[[@CR3]\].

Sirolimus (rapamycin) has been confirmed to be effective for the treatment of LAM \[[@CR4], [@CR5]\]. In our previous report, sirolimus was shown to improve lung function, arterial oxygen levels, 6 min walking distance (6MWD), St George Respiratory questionnaire (SGRQ) scores and vascular endothelial growth factor (VEGF-D) levels \[[@CR6]\]. However, the long-term effects of sirolimus are unclear. Several studies included data on sirolimus treatment over a 2-years period \[[@CR7]--[@CR12]\]. Taveria-DaSilva et al. \[[@CR8]\] reported a study in which 44 patients were treated with sirolimus alone, the changes of predicted values of FEV~1~ and DLCO were − 1.7% ± 0.1% and − 2.2% ± 0.1% before treatment and + 1.7 ± 0.3% and + 0.7% ± 0.3% after treatment (*P* \<  0.001) during a mean of 2.8 years follow up time. In the recent study, Taveira-DaSilva et al. \[[@CR9]\] evaluated the change of pulmonary function of 25 patients with sirolimus treatment, over a period of 4.5 ± 1.6 years, in which annual changes in forced expiratory volume in 1 s (FEV~1~) and diffusion capacity for carbon monoxide (DLCO) were reduced from − 7.4% ± 1.4% to − 0.3% ± 0.5% (*P* \<  0.001) and − 6.4% ± 0.9% to − 0.4% ± 0.5% (*P* \<  0.001), respectively. Johnson et al. \[[@CR10], [@CR11]\] prospectively observed LAM patients treated with sirolimus over 2 years, the mean change in FEV~1~ ranged from − 7 ± 82 ml/year (*n* = 23) to 11 ± 75 ml/year(*n* = 47). The above studies demonstrated that sirolimus effectively improves the lung function in LAM patients. However, it is still unknown whether sirolimus continuously improves or stabilizes lung function over a longer observation period.

Considering sirolimus is used in LAM patients for a long period of time, whether its efficacy can be maintained is a critical question. Safety is another issue for those patients who take sirolimus for many years. In this study, we analyzed the efficacy and safety of sirolimus for up to 4 years.

Method {#Sec2}
======

Study populations {#Sec3}
-----------------

Subjects were from the LAM registry in Peking Union Medical College Hospital (PUMCH), Beijing, China. The diagnosis of LAM was re-evaluated and confirmed according to the recent diagnosis criteria of American Thoracic Society and Japanese Respiratory Society published in 2017 \[[@CR13]\]. Subjects were included if the following criteria were met: (1) sirolimus therapy with follow-up data after treatment, and (2) sirolimus therapy with baseline evaluation (within 3 months of sirolimus initiation). The exclusion criteria included the following: (1) patients with tuberous sclerosis complex, and (2) patients with other malignant tumors, and (3) patients who had undergone lung transplantation. Patients with tuberous sclerosis complex were not included because of limited data of this group of patients.

The protocol of this study was approved by the Ethical Committee of PUMCH (S-K709). All subjects included in this study signed informed consent documents.

The indication of sirolimus was primarily based on reduced lung function (FEV1 less than 70% predicted value) or rapidly declining lung function (FEV1 loss over 90 ml per year) \[[@CR5]\]. Other indications included chylothorax, chylous ascites, angiomyolipomas or repeated pneumothorax, etc. Dosage and dosage adjustment of sirolimus were based on the judgement of the physicians who treated the patient, which have been described in our previous study \[[@CR6]\]. Generally, patients took sirolimus 1 or 2 mg orally once daily. A serum level of 5 to 10 ng/ml sirolimus was considered optimal concentration range. For patients with a serum level \> 10 ng/ml or \< 5 ng/ml, the dose of sirolimus was adjusted according to the clinical symptoms and adverse events.

Study design {#Sec4}
------------

We carefully collected the annual follow-up records of the enrolled subjects for this retrospective analysis. The follow-up visit data comprised pulmonary function tests, arterial blood gas analysis at rest (on room air), 6MWD, Borg dyspnea index, SGRQ, and VEGF-D. The baseline data were defined as those collected within 3 months of sirolimus initiation. The additional data were categorized as pretreatment and posttreatment data, defined as 1 year (± 3 months) or 2 years (± 3 months) before sirolimus initiation and 1 year (± 3 months), 2 years (± 3 months), 3 years (± 3 months), and 4 years (± 3 months) after sirolimus initiation.

Pulmonary function was measured according to the American Thoracic Society/European Respiratory Society (ATS/ERS) Task Force Standardization of Lung Function Testing \[[@CR14]\]. The 6MWD was performed based on ATS guidelines \[[@CR15]\]. Borg dyspnea index was assessed at the end of the 6MWD test. Patients completed the SGRQ according to the provided instructions. The pneumothorax and chylothorax were evaluated by chest X-ray or CT. Degree of pulmonary cystic lesions and renal angiomyolipoma size was evaluated by CT. Adverse events were assessed according to the Common Terminology Criteria for Adverse Events (version 3.0). Serum VEGF-D levels were measured with an enzyme-linked immunosorbent assay (Quantikinine Human VEGF-D Immunoassay, R&D Systems).

Statistical analysis {#Sec5}
--------------------

Normally distributed data are reported as the mean ± SD; data that were not normally distributed are reported as the medians and interquartile ranges (median \[25, 75%\]). The normality of the data was analyzed by the Kolmogorov-Smirnov test. The unpaired *t*-test or Mann-Whitney *U*-test was used to compare continuous variables. The paired *t*-test was used to compare the baseline data with post-treatment data. All reported *P* values are two-sided. *P* values less than 0.05 were considered statistically significant. We used *R* language V3.5.3 (Microsoft, Washington, USA) to build linearmix-effect model in order to assess the effects of sirolimus therapy. Data analyses were also performed in GraphPad Prism V.7.03 (Graphpad, California, USA) and SPSS V.24 (IBM, New York, USA).

Results {#Sec6}
=======

Demographics {#Sec7}
------------

The baseline characteristics and clinical features of the study participants (*n* = 142) are shown in Table [1](#Tab1){ref-type="table"}. Of 142 subjects enrolled, 122, 83, 60 and 32 patients were followed-up for 1, 2, 3 and 4 years respectively. Table 1Baseline demographic and clinical features of patients with lymphangioleiomyomatosisDemographicsNumbersPercentage or valueTotal sample size142100%Age (years)38 ± 9Sex Female142100%Former smoker00%Complications Renal angiomyolipomas33/14223.2% Pneumothorax40/14228.2% Chylothorax48/14233.8% Chyloperitoneum16/14211.3%CT grading^a^ I7/1424.9% II9/1426.3% III119/14283.8%Pulmonary function FEV~1~ (ml)1141622 ± 712 FVC (ml)1142760 ± 645 FEV~1~% pred11458.5 ± 25 FVC% pred11485 ± 20.6 FEV~1~/FVC (%)11457.5 ± 17.9 RV% pred107161.3 ± 79.3 TLC% pred107116.8 ± 103.8 RV/TLC (%)10746.25 ± 13.67 DLCO% pred (*N* = 107)10740.7 ± 21.2Arterial blood gas analysis PaO~2~ (mmHg)12272.3 ± 13.4 P(A-a)O~2~ (mmHg)11443.4 ± 51.1 Borg dyspnea index1322.5 ± 2.1 6MWD (m)133422 ± 113 SGRQ132 Symptoms score13240.4 ± 24.2 Activity score13254.2 ± 24.9 Impacts score13240.5 ± 25.8 Total score13244.8 ± 23.5Serum VEGF-D level (pg/ml)1403318 ± 2578Data: mean ± SD*Abbreviations*: *6MWD* 6-min walking distance, *DLCO* Diffusion capacity for carbon monoxide, *FEV*~1~ Forced expiratory volume in 1 second; *FVC* Forced vital capacity, *PaO*~*2*~ Partial pressure of oxygen; *P(A-a)O*~*2*~ Alveolo-arterial oxygen partial pressure difference, *RV* Residual volume, *SGRQ* St.George's Respiratory Questionnaire, *TLC* Total lung capacity, *VEGF-D* Vascular endothelial growth factor--D. ^a^: According to the degree of lung involvement, CT was classified as I, II and III grades. Grade I was less than 1/3 of the whole lung field, Grade III was more than 2/3, Grade II was between 1/3 and 2/3 \[[@CR16]\]

Sirolimus improves pulmonary function, oxygen levels, exercise capacity and quality of life {#Sec8}
-------------------------------------------------------------------------------------------

Not surprisingly, in comparison to the pretreatment data, the posttreatment data showed that sirolimus significantly improved pulmonary function (FEV~1~, FEV~1~%predicted, FVC, FVC%predicted, FEV~1~/FVC, DLCO), oxygen levels (PaO~2~, P(A-a)O~2~), 6MWD, SGRQ and VEGF-D levels (Table [2](#Tab2){ref-type="table"}). Over a mean duration of 1.4 ± 0.5 years before the beginning of sirolimus therapy, the FEV~1~ decreased by 178 ± 36 ml per year (7.71% ± 1.20% predicted, *P* \<  0.001), and the FVC decreased by − 72 ± 68 ml per year (− 4.11% ± 1.15% predicted, *P* \<  0.001). In contrast, over a mean of 2.2 ± 1.1 years of sirolimus therapy, the FEV~1~ changed by − 10 ± 15 ml per year (0.29% ± 0.48%predicted, *P* \> 0.05), and the FVC increased by 54 ± 22 ml per year (2.78% ± 0.72%predicted, *P* \<  0.001). Table 2Changes in pulmonary function and other indicators per year before and after sirolimus treatmentVariablesBefore treatmentAfter treatmentBefore vs. AfterMean change per year^§^*P* valueMean change per year^§^*P* value*P* valueFEV~1~(ml)-178 ± 36\<  0.001− 10 ± 150.53\<  0.001FVC (ml)−72 ± 680.2954 ± 220.0160.017FEV~1~%pred−7.71 ± 1.20\<  0.0010.29 ± 0.480.42\<  0.001FVC%pred−4.11 ± 1.150.0092.78 ± 0.72\< 0.0010.008FEV~1~/FVC (%)−7.34 ± 1.08\<  0.001−1.40 ± 0.40\< 0.001\<  0.001DLCO%pred−4.12 ± 1.100.002−0.32 ± 0.370.400.017PaO~2~ (mmHg)−5.7 ± 1.3\<  0.0011.8 ± 0.5\< 0.0010.002P(A-a)O~2~ (mmHg)4.5 ± 1.30.002−1.3 ± 0.50.0120.0026MWD (m)−21 ± 6\<  0.00115 ± 3\< 0.001\<  0.001SGRQ total score3.29 ± 2.020.11− 2.65 ± 0.68\< 0.001\<  0.001VEGF-D (pg/ml)− 233 ± 1850.22− 555 ± 96\< 0.001\<  0.001Data: mean ± SD. Data were obtained by using mixed-effects models. ^§^*P* was calculated against a slope = 0. ^¶^*P* was calculated by the slope before sirolimus therapy versus the slope after sirolimus therapy

Pulmonary function changes in patients with chylothorax and those without chylothorax {#Sec9}
-------------------------------------------------------------------------------------

Forty-eight patients were with chylothorax, and 94 patients were without chylothorax. Pulmonary function data were only available in patients with small amount of pleural effusion. Our data showed that baseline VEGF-D levels were higher in patients with chylothorax, however no significant differences were observed in changes of VEGF-D levels and pulmonary functions in patients with and without chylothorax over 4 years treatment (data not shown). The yearly changes of FEV~1~ in patients with and without chylothorax were 0.46% ± 0.76% predicted and 0.10% ± 0.60 predicted (*P* = 0.95), respectively. The yearly change of DLco were − 0.06% ± 0.69% and − 0.45% ± 0.43% predicted (*P* = 0.92).

Long-term effects of sirolimus at 1, 2, 3 and 4 years {#Sec10}
-----------------------------------------------------

The main aim of the study was to investigate the long-term effects of sirolimus. Using paired comparison, we were able to detect the differences of the measurements from the baseline to 1, 2, 3 and 4 years after the initiation of treatment. As shown in Table [3](#Tab3){ref-type="table"}, the FEV~1~ improved significantly in the first year, and the FVC improved in the first and second year; then, the significance disappeared during the subsequent follow-up. There were no changes in the diffusion capacity after treatment. Overall, pulmonary function was maintained after the initiation of sirolimus therapy. Sirolimus could potentially stabilize pulmonary function for up to 4 years. The improvements in PaO~2~, P(A-a)O~2~, 6MWD, and SGRQ were maintained for 3 years and disappeared in the fourth year (Table [3](#Tab3){ref-type="table"}). No worsening was observed except for in FEV~1~/FVC during the follow-up period. The decrease in VEGF-D level was maintained for up to 4 years (Table [3](#Tab3){ref-type="table"}). For chylothorax, one patient accepted thoracic duct surgery and sirolimus treatment at the same time and rapidly achieved a complete remission. Among the patients receiving sirolimus treatment without surgery, 35 patients got complete remission, and 12 patients improved. Table 3Paired comparisons of functional tests and serum VEGF-D levels between the baseline and annual time points during sirolimus treatmentVariable1 year2 years3 years4 yearsBaselineAfter sirolimus*P* valueBaselineAfter sirolimus*P* valueBaselineAfter sirolimus*P* valueBaselineAfter sirolimus*P* valuePulmonary ventilation function*N* = 67*N* = 36*N* = 22*N* = 11 FEV~1~ (ml)1590 ± 6901640 ± 7100.0451640 ± 6101610 ± 6900.4621470 ± 6601520 ± 7400.5601440 ± 5901310 ± 4400.099 FVC (ml)2640 ± 7602830 ± 7000.0042700 ± 6202880 ± 5600.0442680 ± 6602780 ± 6300.3982570 ± 5602800 ± 3800.149 FEV~1~%pred55.97 ± 23.7559.28 ± 24.30.00457.48 ± 21.9758.28 ± 24.60.70554.22 ± 2357.02 ± 26.440.34650.38 ± 21.0949.19 ± 17.750.557 FVC%pred80.85 ± 22.3787.87 ± 24.060.00583.2 ± 17.9489.68 ± 18.030.01983.56 ± 22.2792.08 ± 22.080.05481.32 ± 18.7290.84 ± 15.30.128 FEV~1~/FVC56.27 ± 17.4256.33 ± 18.020.96658.32 ± 20.6653.72 ± 21.820.00053.59 ± 22.152.94 ± 23.070.81254.04 ± 19.945.25 ± 15.170.014Gas exchange*N* = 48*N* = 26*N* = 19*N* = 7 DLCO%pred40.62 ± 20.3441.23 ± 20.420.37846.94 ± 23.8745.23 ± 22.260.19732.86 ± 19.0135.64 ± 16.910.10434.46 ± 17.6530.49 ± 12.710.109Arterial blood gas*N* = 69*N* = 39*N* = 31*N* = 17 PaO~2~ (mmHg)66.99 ± 12.5871.21 ± 14.980.00668.14 ± 12.6175.68 ± 16.5\<  0.00166.34 ± 10.6870.63 ± 13.360.02669.24 ± 9.66274.09 ± 11.020.084 P(A-a) O~2~ (mmHg)41.29 ± 13.5136.67 ± 16.070.01340.6 ± 13.2832.97 ± 17.23\<  0.00142.63 ± 12.1336.76 ± 13.890.00737.89 ± 12.7235.61 ± 11.60.5046-min walk test*N* = 67*N* = 34*N* = 27*N* = 12 6MWD (m)417 ± 122461 ± 105\<  0.001420 ± 120472 ± 98\<  0.001408 ± 105459 ± 1070.004379 ± 145436 ± 960.1572SGRQ*N* = 63*N* = 33*N* = 27*N* = 12 Total score46.11 ± 22.1138.37 ± 22\<  0.00142.85 ± 21.8331.21 ± 21.79\<  0.00148.04 ± 23.2438.93 ± 21.940.007853.25 ± 24.5149.08 ± 21.950.5019Serum VEGF-D level*N* = 89*N* = 50*N* = 34*N* = 15 VEGF-D (pg/ml)3594 ± 31562001 ± 1972\<  0.0013711 ± 37142133 ± 2550\<  0.0013280 ± 22281761 ± 1255\<  0.0013445 ± 24531851 ± 1355\<  0.001

Dosage of sirolimus {#Sec11}
-------------------

The mean dosage of sirolimus was 1.59 ± 0.50 mg/d (range, 1 to 2 mg/d) at the beginning, and it was 1.27 ± 0.47 mg/d (range, 0.5 to 2 mg/d) after an adjustment period of 1--6 months. Ninety patients accepted the tests of the serum concentration of sirolimus in the first year. The average blood sirolimus level was 7.2 ± 2.6 ng/ml (range, 1.5 to 18.6 ng/ml).

Frequencies of adverse events {#Sec12}
-----------------------------

The adverse events that occurred in our study during the observation period are listed in Table [4](#Tab4){ref-type="table"}. In the first year, the most frequent adverse events were mouth ulcer (68.2%), menstrual abnormality (57.9%), acne (34.6%), weakness (11%), diarrhea (6%), and peripheral edema (5.6%). During the next 3 years, the common adverse events were mouth ulcer, menstrual abnormality and acne. However, the incidence rate of mouth ulcer, menstrual abnormality and acne reduced to 23.3, 26.7 and 10% in the fourth year. Occurrence of adverse events could reduce over time (Table [4](#Tab4){ref-type="table"}). We did not observe severe adverse events in our follow-up periods. Three patients required the temporary discontinuation of sirolimus therapy due to menstrual abnormalities, and then restarted the therapy after 3 to 6 months. No other patients had to discontinue sirolimus therapy because of adverse events. Table 4Adverse events while taking sirolimus according to the duration of treatment in patients with LAMTime after sirolimus (years)Number (%)Year 1 (*N* = 107)Year 2 (*N* = 70)Year 3 (*N* = 53)Year 4 (*N* = 30)Mouth ulcer73 (68.2)33 (47.1)22 (41.5)7 (23.3)Menstrual abnormality62 (57.9)34 (48.6)16 (30.2)8 (26.7)Acne37 (34.6)22 (31.4)12 (22.6)3 (10.0)Ovarian cysts^a^17/55 (30.9)10/37 (27.0)6/25 (24.0)1/8 (12.5)Weakness11 (10)1 (1.4)00Peripheral edema6 (5.6)2 (2.9)1 (1.9)1 (3.3)Diarrhea6 (5.6)1 (1.4)00Rash5 (4.7)001 (3.3)Nausea5 (4.7)01 (1.9)0Weight loss5 (4.7)000Arthralgia4 (3.7)001 (3.3)Abdominal pain3 (2.8)2 (2.9)00Pruritus3 (2.8)1 (1.4)00Abdominal distention2 (1.9)000Fever2 (1.9)000Chest pain2 (1.9)1 (1.4)1 (1.9)1 (3.3)Toothache1 (0.9)000Gingival hyperplasia1 (0.9)000Periodontitis1 (0.9)000Herpes zoster1 (0.9)1 (1.4)00Alopecia1 (0.9)000Headache1 (0.9)000Dizziness1 (0.9)000Palpitation1 (0.9)000Myalgia1 (0.9)000Tenosynovitis1 (0.9)000^a^based on patients evaluated

Discussion {#Sec13}
==========

Whether the efficacy of sirolimus can be maintained during long-term treatment is a critical question. We partially answered this question in the present study. We found improvements of sirolimus in the following parameters in patients after beginning sirolimus treatment: the FEV~1~ in the first year; the FVC in the first and second year; arterial oxygen levels, exercise capacity and quality of life in the first, second and third year; and the VEGF-D levels in all 4 years. An encouraging finding was that most measurements improved or stabilized during 4-year observations after sirolimus treatment.

Current clinical trials usually observed 12--24 months of sirolimus treatment. Several studies included observations over 2 years. In studies with 2--4 years observation, the increase in the FEV~1~ varied from 11 ml/year to 50 ml/year after starting sirolimus treatment \[[@CR6], [@CR7], [@CR10]--[@CR12]\]. In a 4-year prospective study, the mean change in the FEV~1~ in patients not receiving sirolimus was -70 ml /year (*n* = 66), while the mean change in patients receiving sirolimus was 7 ml/year (*n* = 23) \[[@CR10]\]. Taveira-DaSilva et al. \[[@CR9]\] observed 25 patients for 4.5 years, and the FEV~1~ and DLCO changed slightly. The change of FEV~1~ was − 10 ml/year (*P* = 0.53) and the FVC increased by 54 ml/year (*P* = 0.016*)* in our study. In the paired comparison analysis, we found that the FEV~1~ benefited most from sirolimus in the first year, and the FVC benefited in the first 2 years. No significant reduction in pulmonary function was observed over the 4 years. The efficacy of sirolimus can be maintained for at least 4 years.

Higher VEGF-D levels were observed more frequently in patients with lymphatic disease who presented with chylous pleural effusion or ascites than in patients without lymphatic involvement \[[@CR17]\]. Several studies reported that compared with patients without lymphatic disease, patients with lymphatic involvement may experience a great improvement in pulmonary function after starting sirolimus therapy \[[@CR7], [@CR9]\]. Taveira-DaSilva et al. \[[@CR9]\] observed that the effects of sirolimus on VEGF-D levels and DLCO were especially marked in patients with LAM with lymphatic involvement than those without lymphatic involvement. For patients with or without limited small amount of chylothorax, improvement of pulmonary function was similar.

The safety profile is satisfactory. Patients tolerated sirolimus treatment very well. The rate of adverse effects decreased during the follow-up. We also analyzed the group of patients who were followed up for 3 and 4 years, the rate of adverse effects were decreased over time (data not shown).

Anyway, we still need to be cautious in observing long-term adverse effects from the treatment. LAM patients use sirolimus for many years, and it is important to monitor their progress and safety data regularly, at least once a year. Novel therapies for LAM are urgently needed for use when sirolimus cannot be used because of insensitivity or resistance of sirolimus.

The limitations of this study include its retrospective nature and the limited sample size during observation, as only 32 patients had data for all 4 years. Beginning in 2016, a national LAM registry in China was planned that will recruit 800 LAM patients and conduct yearly follow-up. We hope that some unanswered questions will be clarified in future studies.

In conclusion, sirolimus therapy is effective at improving or stabilizing pulmonary function, oxygen levels, exercise capacity, and quality of life in patients with LAM for up to 4 years. VEGF-D maintained at lower level for 4 years after the initiation of treatment. Adverse events related to sirolimus was mild during the follow-up period.
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